A61K 31/7125
Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5'
Official title: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K31/7125 (Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5') appears on 553 US grants and 1,227 published applications in this corpus.
Search patents in A61K- Granted patents
- 553
- Published applications
- 1,227
- Assignees
- 537
- Inventors
- 2,052
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 4 | 0 |
| 1999 | 5 | 0 |
| 2000 | 4 | 0 |
| 2001 | 11 | 0 |
| 2002 | 5 | 11 |
| 2003 | 4 | 21 |
| 2004 | 5 | 15 |
| 2005 | 1 | 28 |
| 2006 | 3 | 12 |
| 2007 | 5 | 7 |
| 2008 | 2 | 11 |
| 2009 | 6 | 25 |
| 2010 | 14 | 25 |
| 2011 | 15 | 17 |
| 2012 | 12 | 14 |
| 2013 | 12 | 26 |
| 2014 | 19 | 34 |
| 2015 | 26 | 38 |
| 2016 | 26 | 39 |
| 2017 | 29 | 47 |
| 2018 | 27 | 77 |
| 2019 | 40 | 78 |
| 2020 | 40 | 81 |
| 2021 | 46 | 92 |
| 2022 | 42 | 99 |
| 2023 | 29 | 97 |
| 2024 | 48 | 109 |
| 2025 | 38 | 89 |
| 2026 | 31 | 135 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Blood-brain barrier permeable heteroduplex nucleic acid29 Sep 2026US 12,746,253 B2National University Corporation Tokyo Medical and Dental University
- Compound, method and pharmaceutical composition for regulating expression of ataxin 315 Sep 2026US 12,735,705 B2Tanabe Pharma Corporation
- Antagonism as a therapy for TDP-43 proteinopathies25 Aug 2026US 12,716,065 B2University of Southern California
- Methods of reducing or preventing clostridioides difficile colonization18 Aug 2026US 12,708,119 B2Liv Process, Inc.
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Compositions and methods for regulating expression of atxn28 Oct 2026US 2026/0308591 A1Riboway Therapeutics, Inc.
- Trems for use in correction of missense mutations1 Oct 2026US 2026/0294955 A1Flagship Pioneering Innovations VI, LLC
- Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same1 Oct 2026US 2026/0297581 A1Aligos Therapeutics, Inc.
- Alk7 rna interference agents1 Oct 2026US 2026/0297588 A1Eli Lilly and Company
Most cited
By later US patents
- Immunostimulatory nucleic acid molecules472US 6,207,646 B1Coley Pharmaceutical Group, Inc. · 2001
- Immunostimulatory nucleic acid molecules461US 6,239,116 B1Coley Pharmaceutical Group, Inc. · 2001
- Immunomodulatory oligonucleotides335US 6,194,388 B1Coley Pharmaceutical Group, Inc. · 2001
- Immunostimulatory nucleic acid molecules for activating dendritic cells265US 6,429,199 B1University of Iowa Research Foundation · 2002
- 2'-modified oligonucleotides253US 6,005,087 AIsis Pharmaceuticals, Inc. · 1999